Skip to content

Liver Diseases in PLWH

Epidemiological Investigation of HIV-infected Patients Complicated With Liver Disease in Zhejiang Province

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04446156
Enrollment
3000
Registered
2020-06-24
Start date
2020-05-26
Completion date
2020-12-30
Last updated
2020-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS, Liver Diseases

Brief summary

In Highly Active Antiretroviral Therapy era, fatty liver has become an important cause of liver function damage in people living with HIV (PLWH). There are a large number of PLWH in China who are infected with hepatitis B virus and hepatitis C virus. HIV, hepatitis B virus, hepatitis C virus, drugs, alcohol, etc. affect each other, which makes the cause, diagnosis, and treatment of liver function damage in PLWH complicated in China. The investigators plan to conduct a large-scale questionnaire survey among PLWH in Zhejiang Province to assess liver function, detect liver Injuries early, and analyze HIV, hepatitis B virus, hepatitis C virus, anti-HIV drugs, alcohol and other factors associate with liver injuries in PLWH, to provide basis for the treatment and prevention of liver disease in PLWH in eastern China.

Interventions

None listed

Sponsors

First Affiliated Hospital of Zhejiang University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years old; * Non-hospitalized patients diagnosed with HIV infection; * Sign the informed consent voluntarily.

Exclusion criteria

* Severe active infection requiring parenteral antibiotics or antifungal treatment within 30 days before the assessment; * Other major chronic diseases that may affect health-related quality of life, such as extrahepatic malignant tumors; * Psychotic patients, patients with severe cognitive or neurological deficits; * Women during pregnancy and lactation; * Those who refuse to sign informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of liver disease in PLWH2020-12-31The overall prevalence of liver disease in PLWH and the prevalence of hepatitis B, C, and fatty liver

Countries

China

Contacts

Primary ContactBiao Zhu, PhD.
zhubiao1207@zju.edu.cn+86 13906535457
Backup ContactYongzheng Guo, MD.
ggyongzheng08@zju.edu.cn+86 13645814389

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026